INOVIO PHARMACEUTICALS, INC.
INO evidence brief
What we can confirm
- BioSniper Score:
- 5.6 / 10
- Market Cap:
- $129.2M
- Lead Asset:
- vgx-3100 (Phase 3)
What it means
What to watch
Prepared research question
What matters most for INO—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · INO
INOVIO is a clinical-stage biotechnology company developing DNA medicines for HPV-related diseases, cancer, and infectious diseases, with its lead candidate INO-3107 under FDA review for recurrent respiratory papillomatosis (RRP) and a PDUFA date of October 30, 2026 [sec · filed 2026-04-07].
Key risk: Cash runway limited
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$129.2M
Cash Runway
—
Lead Asset
vgx-3100 (Phase 3)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 4 clinical trials for INOVIO PHARMACEUTICALS, INC..
INOVIO is a clinical-stage biotechnology company developing DNA medicines for HPV-related diseases, cancer, and infectious diseases, with its lead candidate INO-3107 under FDA review for recurrent respiratory papillomatosis (RRP) and a PDUFA date of October 30, 2026 [sec · filed 2026-04-07].
- Lead candidate INO-3107 (for RRP) has a PDUFA target date of October 30, 2026, with the BLA accepted under the Accelerated Approval Program [sec · filed 2026-04-07].
- Cash and equivalents were $31.5M as of 2026-06-30, with net income of -$6.0M and shareholders' equity of $4.4M [sec].
- Cash runway is expected to extend into late first quarter 2027, including net proceeds from the July 2026 Offering [sec_mda · as of 2026-08-12].
- Pipeline includes a Phase 3 trial for INO-3112 (HPV-related oropharyngeal cancer) in collaboration with Coherus BioSciences, with FDA alignment on trial design [sec · filed 2026-07-02].
- The company's DNA medicine platform uses proprietary CELLECTRA devices to deliver DNA plasmids that produce disease-fighting proteins in the body [sec · filed 2026-07-02].
What works
- INO-3107 has been accepted for FDA review under the Accelerated Approval Program, with a defined PDUFA date, indicating regulatory progress [sec · filed 2026-04-07].
- The company has secured FDA alignment on the design of a planned Phase 3 trial for INO-3112 in oropharyngeal cancer, de-risking a key pipeline program [sec · filed 2026-07-02].
- The DNA medicine platform is versatile, with applications across HPV-related diseases, cancer, and infectious diseases, offering multiple potential catalysts [sec · filed 2026-04-07].
What to weigh
- The company reported zero total revenue and a net loss of $6.0M as of 2026-06-30, with cash runway only extending into late first quarter 2027 [sec] [sec_mda · as of 2026-08-12].
- The FDA noted a preliminary potential review issue regarding INO-3107's eligibility for the accelerated approval program, which could delay or derail approval [sec · filed 2026-04-07].
- The company is dependent on raising additional capital to continue operations beyond early 2027, and has already eliminated roles to conserve cash [sec_mda · as of 2026-08-12].
From the filings
Quoted directly from source documents.
INO-3107 BLA accepted under Accelerated Approval Program with PDUFA date October 30, 2026
“Biologics License Application (BLA) for INO-3107 accepted for review under the Accelerated Approval Program as a potential treatment for adults with Recurrent Respiratory Papillomatosis (RRP) by the U.S. Food and Drug Administration (FDA); target Prescription Drug User Fee Act (PDUFA) date October 30, 2026.”
SEC filings · April 7, 2026
Cash runway extends into late first quarter 2027
“We expect our cash runway, including the net proceeds from the July 2026 Offering, to extend into late first quarter 2027, without giving effect to any further capital raising activities that we may undertake.”
SEC MD&A · August 12, 2026
FDA noted a preliminary potential review issue regarding accelerated approval eligibility
“That includes addressing the preliminary potential review issue they noted in their file acceptance letter regarding eligibility for the accelerated approval program.”
SEC filings · April 7, 2026
Catalyst timeline
- 2018-05-31 · Phase 2 start for INO-5401/INO-9012 in glioblastoma — An open-label, multi-center trial of INO-5401 and INO-9012 delivered by electroporation in combination with REGN2810 in subjects with newly-diagnosed glioblastoma.
- 2020-10-07 · Phase 2 start for INO-3107 in RRP — An open-label, multi-center study of INO-3107 with electroporation in subjects with HPV-6- and/or HPV-11-associated recurrent respiratory papillomatosis.
- 2021-06-21 · Phase 2 start for INO-4700 (MERS vaccine) — Study to evaluate the safety, tolerability and immunogenicity of INO-4700 for Middle East Respiratory Syndrome Coronavirus in healthy volunteers.
- 2025-12-31 · Trial readout for INO-4700 — Safety, tolerability, and immunogenicity data readout for the DNA-based vaccine INO-4700 against MERS.
Risks & what to watch (4)›
Key risks
- Cash runway limited — Cash runway extends only to late Q1 2027; company must raise additional capital to continue operations [sec_mda · as of 2026-08-12].
- Regulatory risk for INO-3107 — FDA flagged a preliminary issue regarding accelerated approval eligibility for INO-3107 [sec · filed 2026-04-07].
- No revenue and ongoing losses — Company reported $0 revenue and a net loss of $6.0M as of 2026-06-30 [sec].
- Dependence on partnerships — Pipeline advancement relies on collaborations (e.g., Coherus, ApolloBio) which may introduce execution risk [sec · filed 2026-07-02].
What to watch
- FDA decision on INO-3107 by October 30, 2026 PDUFA date [sec · filed 2026-04-07].
- Ability to raise additional capital to extend cash runway beyond Q1 2027 [sec_mda · as of 2026-08-12].
- Progress of Phase 3 trial for INO-3112 in oropharyngeal cancer, including enrollment and data readouts [sec · filed 2026-07-02].
- Outcome of ApolloBio's Phase 3 trial of VGX-3100 in China and potential regulatory submission [pipeline].
Sources: Catalysts · News · Pipeline · SEC filings · SEC MD&A · Generated October 6, 2026 · How we verify sources →
Run INOVIO PHARMACEUTICALS, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available INOVIO PHARMACEUTICALS, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 10.30 · 0% dilution
Lead: Phase 3
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
100
Total value held
$54.1M
| Holder | Shares | Value |
|---|---|---|
| fmr llc | 9,339,614 | $16.3M |
| janus henderson group plc | 3,308,406 | $5.8M |
| vanguard capital management llc | 2,901,208 | $5.0M |
| boxer capital management, llc | 2,370,122 | $4.1M |
| d. e. shaw & co., inc. | 2,212,819 | $3.9M |
| adar1 capital management, llc | 1,470,108 | $2.6M |
| millennium management llc | 1,410,845 | $2.5M |
| eversept partners, lp | 1,035,360 | $1.8M |
| adage capital partners gp, l.l.c. | 804,958 | $1.4M |
| geode capital management, llc | 801,504 | $1.4M |
Showing top 10 of 100 institutional holders of INOVIO PHARMACEUTICALS, INC.. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 17.9%
- Days to cover
- 4.9
- Shares short
- 12,768,874
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
INO short interestGovernance
Frequently asked questions
What is the AI investment thesis for INOVIO PHARMACEUTICALS, INC.?
INOVIO is a clinical-stage biotechnology company developing DNA medicines for HPV-related diseases, cancer, and infectious diseases, with its lead candidate INO-3107 under FDA review for recurrent respiratory papillomatosis (RRP) and a PDUFA date of October 30, 2026 [sec · filed 2026-04-07].
What is INOVIO PHARMACEUTICALS, INC.'s lead drug candidate?
INOVIO PHARMACEUTICALS, INC.'s most advanced tracked candidate is vgx-3100 (Phase 3) for HPV-related cervical HSIL.
Who is the CEO of INOVIO PHARMACEUTICALS, INC.?
Dr. Jacqueline E. Shea Ph.D. is the chief executive officer of INOVIO PHARMACEUTICALS, INC. (INO).
Where is INOVIO PHARMACEUTICALS, INC. headquartered?
INOVIO PHARMACEUTICALS, INC. (INO) is headquartered in Plymouth Meeting, PA, United States.
What therapeutic areas does INOVIO PHARMACEUTICALS, INC. focus on?
INOVIO PHARMACEUTICALS, INC. develops therapies across Oncology, Immunology, Respiratory.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.